Advertisement

Behandlung der Myokardischämie mit Kalziumantagonisten

  • Wolf Rafflenbeul
Conference paper

Zusammenfassung

Kalzium ist das häufigste Kation im menschlichen Körper. Seine Bewegungen durch die Membran erregbarer Zellen und seine Akkumulation innerhalb der Zelle sind von fundamentaler Bedeutung für die spezifische Aktivität von Geweben. Allgemein ist die Konzentration von Kalzium im Zytosol nur ein geringer Anteil der Kalziumkonzentration im Plasma und weitgehend unabhängig von den normalen Schwankungen im Plasma-Kalzium [12]. Daher liegt eine wesentliche Voraussetzung für die intrazelluläre Kalziumhomöostase in einem sehr präzisen Modulationsmechanismus der Eintritts- und Austrittsrate von Kalzium im Zusammenwirken mit der Funktion des sarkoplasmatischen Retikulums und der Mitochondrien. Eine Steigerung des intrazellulären Kalziums auf abnormal hohe Spiegel kann Zellschäden oder Zelltod verursachen. Zellmembranen weisen eine niedrige Permeabilität für Kalzium auf, das in die Zellen im wesentlichen durch spezifische Kalziumkanäle eintritt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allen DG, Orchard CH (1983) Intracellular calcium concentration during hypoxia and metabolic inhibition in mammalian ventricular muscle. J Physiol (London) 339: 107–122Google Scholar
  2. 2.
    Amende I, Simon R, Hood WP, Hetzer R, Lichtlen PR (1983) Intracoronary nifedipine in human beings: magnitude and time course of changes in left ventricular contraction/relaxation and coronary sinus blood flow. J Am Coll Cardiol 2: 1141–1145PubMedCrossRefGoogle Scholar
  3. 3.
    Bala Subramanian V, Bowles M, Penalver H, Davies AB, Raftery EB (1981) Verapamil in ischemic heart disease — an objective study in 100 patients. In: Zanchetti A, Krikler DM (eds) Calcium Antagonism in Cardiovascular Therapy. Excerpta Medica, Amsterdam, pp 118–139Google Scholar
  4. 4.
    Bala Subramanian V (1983) Calcium antagonists in chronic stable angina pectoris. Excerpta Medica, AmsterdamGoogle Scholar
  5. 5.
    Bala Subramanian V, Khurmi NS, Bowles MJ, O’Hara M, Raftery EB (1983) Objective evaluation of three dose levels of diltiazem in patients with chronic stable angina. J Am Coll Cardiol 1: 1144–1153PubMedCrossRefGoogle Scholar
  6. 6.
    Benham CD, Tsien RW (1987) A novel receptor-operated calcium-permeable channel activated by ATP in smooth muscle. Nature 328: 275–278PubMedCrossRefGoogle Scholar
  7. 7.
    Bier C, Klassen G, Hütter I, Marner O, Mogensen L, Zborowska-Sluis D (1978) Mitochondrial protection by nifedipine in ischemic myocardium. Circulation 57/58 (Suppl. II) I I: 99 (abstr.)Google Scholar
  8. 8.
    Boehm C, Christi HL (1983) Comparative studies of efficacy of nifedipine and molsidomin for the treatment of stable angina pectoris. Therapiewoche 33: 4604–4613Google Scholar
  9. 9.
    Bolton TB (1979) Mechanism of action of transmitters and other substances on smooth muscle. Physiol Rev 59: 606–621PubMedGoogle Scholar
  10. 10.
    Bourdillon PD, Poole-Wilson PA (1982) The effects of verapamil, quiescence and cardioplegia on calcium exchange and mechanical function in ischemic rabbit myocardium. Circ Res 50: 360–368PubMedGoogle Scholar
  11. 11.
    Brodsky SJ, Cutler SS, Weiner DA, McCabe CH, Ryan TJ, Klein MD (1982) Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled, randomized crossover study. Circulation 66: 569–574PubMedCrossRefGoogle Scholar
  12. 12.
    Carafoli E (1984) How calcium crosses plasma membranes including the sarcolemma. In: Opie LH (ed) Calcium Antagonists and Cardiovascular Disease Raven Press, New York, pp 29–41Google Scholar
  13. 13.
    Casteels R, Droogmans G (1982) Membrane potential and excitation — contraction coupling in smooth muscle. Fed Proc 41: 2879–2884PubMedGoogle Scholar
  14. 14.
    Cheung JY, Bonventre JV, Malis CD, Leaf A (1986) Calcium and ischemic injury. N Engl J Med 314: 1670–1676PubMedCrossRefGoogle Scholar
  15. 15.
    Chew CC, Hecht HS, Collett JT, McAllister RG, Singh BN (1981) Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 47: 917–922PubMedCrossRefGoogle Scholar
  16. 16.
    Cobbold PH, Bonrue PK (1984) Aequorin measurements of free calcium in single heart cells. Nature 312: 444–446PubMedCrossRefGoogle Scholar
  17. 17.
    Daly MJ, Elz JS, Nayler WG (1985) The effect of verapamil on ischemia-induced changes to the sarcolemma. J Mol Cell Cardiol 17: 667–674PubMedCrossRefGoogle Scholar
  18. 18.
    Daniel WG, Engel HJ, Lichtlen PR (1984) Effects of Ca-antagonists on regional myocardial blood flow. In: Althaus U, Burckhardt D, Vogt E (eds) Ca-Antagonism. International Symposium on Calcium-Antagonism. Universimed, Frankfurt, pp 152–162Google Scholar
  19. 19.
    De Jong JW, Harmsen E, De Tombe PP, Keijzer E (1982) Nifedipine reduces adenine nucleotide breakdown in ischemic rat heart. Eur J Pharmacol 81: 89–94PubMedCrossRefGoogle Scholar
  20. 20.
    Deanfield J, Wright C, Fox K (1983) Treatment of angina pectoris with nifedipine: importance of dose titration. Br Med J 286: 1467–1470CrossRefGoogle Scholar
  21. 21.
    Ebner F (1975) Survey of the results of world wide clinical trials with nifedipine. In: Hashimoto K, Kimura E, Kobayashi T (eds) First International Nifedipine Symposium. University Tokyo press, Tokyo, pp 282–290Google Scholar
  22. 22.
    Elz JS, Panagiotopoulos S, Nayler WG (1989) Reperfusion-induced calcium gain after ischemia. Am J Cardiol 63: 7E - 13EPubMedCrossRefGoogle Scholar
  23. 23.
    Engel HJ, Lichtlen PR (1981) Beneficial enhancement of coronary blood flow by nifedipine. Comparison with nitroglycerin and beta-blocking agents. Am J Med, 71: 658–666Google Scholar
  24. 24.
    Finkel AS, Hirst GDS, van Helden DF (1984) Some properties of excitatory junction currents recorded from submucosal arterioles of guinea-pig ileum. J Physiol 351: 87–98PubMedGoogle Scholar
  25. 25.
    Fleckenstein A (1983) History of calcium antagonists. Circ Res 52: I3 — I16PubMedGoogle Scholar
  26. 26.
    Freudenberg H, Lichtlen PR (1981) Das normale Wandsegment bei Koronarstenose — eine postmortale Studie. Z Kardiol 70: 863–869PubMedGoogle Scholar
  27. 27.
    Gerst enblith G, Ouyang P, Achuff SC, Bulkley BH, Becker LC, Mellits ED, Baughman KL, Weiss JL, Flaherty JT, Kallman CH, Llewellyn M, Weisfeldt ML (1982) Nifedipine in unstable angina: a double-blind randomized trial. N Engl J Med 306: 885–889CrossRefGoogle Scholar
  28. 28.
    Ginsburg R, Bristow MR, Harrison DC, Stinson EB (1980) Studies with isolated human coronary arteries: some general observations, potential mediators of spasm, role of calcium antagonists. Chest 78 [Supp1]: 180–186PubMedCrossRefGoogle Scholar
  29. 29.
    Go M, Hollenberg M (1984) Improved efficacy of high dose versus medium and low dose diltiazem therapy for chronic stable angina pectoris. Am J Cardiol 53: 669–673PubMedCrossRefGoogle Scholar
  30. 30.
    Godfraind T, Finet M, Socrates Lima J, Miller RC (1984) Contractile activity of human coronary arteries and human myocardium in vitro and their sensitivity to calcium entry blockade by nifedipine. J Pharmacol Exp Ther 230: 514–518PubMedGoogle Scholar
  31. 31.
    Godfraind T (1986) Calcium entry blockade and excitation-contraction coupling in the cardiovascular system (with an attempt of pharmacological classification). Acta Pharmacol Toxicol 58 [Suppl II1: 5–30Google Scholar
  32. 32.
    Godfraind T, Egleme C, Finet M, Debande B, Jaumin P (1987) Comparison of nifedipine and nisoldipine on human arteries and human cardiac tissues in vitro. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987, Springer, Berlin Heidelberg New York, pp 36–44CrossRefGoogle Scholar
  33. 33.
    Godfraind T (1987) Classification of the calcium antagonists. Am J Cardiol 59: 11B - 23BPubMedCrossRefGoogle Scholar
  34. 34.
    Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G (1987) Silent ischemia predicts infarction and death during two year follow-up of unstable angina. J Am Coll Cardiol 10: 756–760PubMedCrossRefGoogle Scholar
  35. 35.
    Guazzi MD, Fiorentini C, Olivari MT, Bartorelli A, Necchi G, Polese A (1980) Short-and long-term efficacy of a calcium antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation 61: 913–919PubMedGoogle Scholar
  36. 36.
    Gunther S, Muller JE, Mudge GH, Grossman W (1981) Therapy of coronary vasoconstriction in patients with coronary artery disease. Am J Cardiol 47: 157–162PubMedCrossRefGoogle Scholar
  37. 37.
    Henry PD, Shuchleib R, Davis J, Weiss ES, Sobel BE (1977) Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol 233: H677 — H680PubMedGoogle Scholar
  38. 38.
    Henry PD, Shuchleib R, Clark RE, Perez JE (1979) Effects of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 44: 817–824PubMedCrossRefGoogle Scholar
  39. 39.
    Heusch G, Deussen A (1984) Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses. J Cardiovasc Pharmacol 6: 378–383PubMedCrossRefGoogle Scholar
  40. 40.
    Heusch G, Guth BD, Seitelberger R, Ross J (1987) Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation 75: 482–490PubMedCrossRefGoogle Scholar
  41. 41.
    Hill JA, Feldman RL, Pepine CJ, Conti CR (1982) Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 49: 431–438PubMedCrossRefGoogle Scholar
  42. 42.
    Hossack KF, Pool PE, Steele P, Crawford MH, De Maria AN, Cohen LS, Ports TA (1982) Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol 49: 567–572PubMedCrossRefGoogle Scholar
  43. 43.
    Hugenholtz PG, Michels HR, Serruys PW, Brower RW (1981) Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia. Am J Cardiol 47: 163–173PubMedCrossRefGoogle Scholar
  44. 44.
    Hugenholtz PG, Serruys PW, Fleckenstein A, Nayler W (1986) Why calcium antagonists will be most useful before or during early myocardial ischemia and not after infarction has been established. Eur Heart J 7: 270–278PubMedGoogle Scholar
  45. 45.
    Ichihara K, Haneda T, Onodera S, Abiko Y (1987) Inhibition of ischemia-induced subcellular redistribution of lysosomal enzymes in the perfused rat heart by the calcium entry blocker diltiazem. J Pharmacol Exp Ther 242: 1109–1113PubMedGoogle Scholar
  46. 46.
    Jenkins RM, Nagle RE (1982) The symptomatic and objective effects of nifedipine in combination with betablocker therapy in severe angina pectoris. Postgrad Med J 58: 697–700PubMedCrossRefGoogle Scholar
  47. 47.
    Jennings RB, Schaper J, Hill ML, Steenbergen G, Reimer KA (1985) Effects of reperfusion late in the phase of reversible ischemic injury. Circ Res 56: 262–278PubMedGoogle Scholar
  48. 48.
    Jolly SR, Gross GJ (1980) Improvement in ischemic myocardial blood flow following a new calcium antagonist. Am J Physiol 239: H163 — H171PubMedGoogle Scholar
  49. 49.
    Jost S, Rafflenbeul W, Mogwitz B, Nellessen U, Hecker H, Ahr G, Lichtlen PR (1987) Coronary vasomotility with different intravenous doses of nisoldipine. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin, Heidelberg, New York, pp 165–170CrossRefGoogle Scholar
  50. 50.
    Jost S, Rafflenbeul W, Lichtlen PR (1989) Assessment of the vasomotility of epicardial coronary arteries with quantitative coronary angiography. Z Kardiol 78 [Suppl 6]: 143–148PubMedGoogle Scholar
  51. 51.
    Kaltenbach M, Schulz W, Kober G (1979) Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 44: 832–836PubMedCrossRefGoogle Scholar
  52. 52.
    Kihara Y, Grossmann W, Morgan JP (1989) Direct measurement of changes in intracellular calcium transient during hypoxia, ischemia and reperfusion of the intact mammalian heart. Circ Res 65: 1029–1044PubMedGoogle Scholar
  53. 53.
    Koch G (1980) Beta-receptor and calcium blockade in ischemic heart disease: effects on systemic and pulmonary hemodynamics and on plasma catecholamines at rest and during exercise. In: Puech P, Krebs R (eds) 4th International Adalat Symposium. Excerpta Medica, Amsterdam, pp 131–142Google Scholar
  54. 54.
    Lange R, Ingwall J, Hale SL, Alker KJ, Braunwald E, Kloner RA (1984) Preservation of high-energy phosphates by verapamil in reperfused myocardium. Circulation 70: 734–741PubMedCrossRefGoogle Scholar
  55. 55.
    Lee HC, Mohabir R, Smith N, Franz MR, Clusin WT (1988) Effects of ischemia on calcium-dependent fluorescence transients in rabbit hearts containing indo 1: correlation with mono-phasic action potentials and contraction. Circulation 78: 1047–1059PubMedCrossRefGoogle Scholar
  56. 56.
    Liang CS, Coplin B, Wellington K (1985) Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: a long term, randomized, double blind, crossover study. Am J Cardiol 55: 9E - 14EPubMedCrossRefGoogle Scholar
  57. 57.
    Lindenberg BS, Weiner DA, McCabe CH, Cutler SS, Ryan TJ, Klein MD (1983) Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 2: 1129–1133PubMedCrossRefGoogle Scholar
  58. 58.
    Lodge NJ, Van Breemen C (1988) Calcium pathways mediating agonist-activated contraction of vascular smooth muscle and EDRF release from endothelium. In: Morad M, Nayler W, Kazda S, Schramm M (eds) The Calcium Channel: Structure, Function and Implications. Springer, Berlin Heidelberg New York, pp 283–292Google Scholar
  59. 59.
    Low RI, Takeda P, Mason DT, DeMaria AN (1982) The effects of calcium channel blocking agents on cardiovascular function. Am J Cardiol 49: 547–553PubMedCrossRefGoogle Scholar
  60. 60.
    Malacoff RF, Lorell BH, Mudge GH, Holman BL, Idoine J, Bifolck L, Cohn PF (1982) Beneficial effect of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 65 [Suppl. 4132–137Google Scholar
  61. 61.
    Mas-Oliva J, Nayler WG (1980) The effect of verapamil on the calcium-transporting and calcium ATPase activity of isolated cardiac sarcolemmal preparations. Br J Pharmacol 70: 617–624PubMedGoogle Scholar
  62. 62.
    Matsuzaki M, Guth BD, Tajimi T, Kemper WS, Ross J (1985) Effect of the combination of diltiazem and atenolol on exercise-induced regional myocardial ischemia in conscious dogs. Circulation 72: 233–243PubMedCrossRefGoogle Scholar
  63. 63.
    Mayhan WG, Joyner WL (1984) The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc Res 28: 159–179PubMedCrossRefGoogle Scholar
  64. 64.
    Mc Donagh PF, Roberts DJ (1986) Prevention of transcoronary macromolecular leakage after ischemia-reperfusion by the calcium entry blocker nisoldipine. Circ Res 58: 127–136Google Scholar
  65. 65.
    Millard R, Grupp G, Grupp IL, Disalvo J, De Pover A, Schwartz A (1983) Chronotropic, inotropic and vasodilator actions of diltiazem, nifedipine and verapamil. A comparative study of physiological responses and membrane receptor activity. Circ Res 52 [Suppl I]: 29–39Google Scholar
  66. 66.
    Mueller HS, Chahine RA (1981) Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina. Am J Med 71: 645–657PubMedCrossRefGoogle Scholar
  67. 67.
    Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts P, Pearle D, Toorey ZG, Schneider JF, Serfas DH (1984) Nifedipine therapy for threatened and acute myocardial infarction: a randomized double-blind placebo-controlled comparison. Circulation 69: 740–747PubMedCrossRefGoogle Scholar
  68. 68.
    Nayler WG, Gran A, Slade A (1976) A protective effect of verapamil on hypoxic heart muscle. Cardiovasc Res 10: 650–657PubMedCrossRefGoogle Scholar
  69. 69.
    Nayler WG, Ferrari R, Williams A (1980) Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondria] function in the ischemic and reperfused myocardium. Am J Cardiol 46: 242–248PubMedCrossRefGoogle Scholar
  70. 70.
    Nayler WG, Sturrock WJ (1985) Inhibitory effect of calcium antagonists on the depletion of cardiac norepinephrine during postischemic reperfusion. J Cardiovasc Pharmacol 7: 581–587PubMedCrossRefGoogle Scholar
  71. 71.
    Nayler WG, Elz JS (1986) Reperfusion injury: laboratory artifact or clinical dilemma? Circulation 74: 215–221PubMedCrossRefGoogle Scholar
  72. 72.
    Nayler WG, Panagiotopoulos S, Elz JS, Sturrock WJ (1987) Fundamental mechanisms of action of calcium-antagonists in myocardial ischemia. Am J Cardiol 79: 75B - 83BCrossRefGoogle Scholar
  73. 73.
    Nayler W (1988) Calcium Antagonists. Academic Press, London, San DiegoGoogle Scholar
  74. 74.
    Nellessen U, Rafflenbeul W, Jost S, Daniel W, Hecker H, Lichtlen PR (1987) Koronarweitenänderung nach sublingualer and intravenöser Nifedipinapplikation in Korrelation zu Plasmaspiegeln. Z Kardiol 76: 329–339PubMedGoogle Scholar
  75. 75.
    Nigdikar SV, Bowditch J, Dow JW (1986) Calcium antagonists and adenine nucleotide metabolism in rat heart. Cardiovasc Res 20: 604–608PubMedCrossRefGoogle Scholar
  76. 76.
    Opie LH (1987) Calcium channel antagonists, part I: fundamental properties: mechanisms, classification, sites of action. Cardiovasc Drugs Ther 1: 411–430PubMedCrossRefGoogle Scholar
  77. 77.
    Otsu F, Kishida H (1987) Antianginal efficacy of nisoldipine in patients with unstable angina pectoris: evaluation on Holter ECG. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 115–122CrossRefGoogle Scholar
  78. 78.
    Parodi O, Maseri A, Simonetti I (1979) Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit. Br Heart J 41: 167–174Google Scholar
  79. 79.
    Petru MA, Crawford MH, Sorenson SG, Chaudhuri TK, Levine S, O’Rourke RA (1983) Short-and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease: a placebo-controlled randomized, double-blind crossover study. Circulation 68: 139–147PubMedCrossRefGoogle Scholar
  80. 80.
    Pine MD, Citron D, Bailley DJ, Butman S, Plasencia GO, Landa DW, Wong RK (1982) Verapamil versus placebo in relieving stable angina pectoris. Circulation 65: 17–22PubMedCrossRefGoogle Scholar
  81. 81.
    Poole-Wilson PA, Harding DP, Bourdillon PDV, Tones MA (1984) Calcium out of control. J Mol Cell Cardiol 16: 175–187PubMedCrossRefGoogle Scholar
  82. 82.
    Previtali M, Salerno JA, Pancipoli C, Guasti L, Chimienti M, Montemantini C (1986) Short term effectiveness of nifedipine, diltiazem and verapamil in Prinzmetal’s variant angina. Evaluation by Holter monitoring and ergometrine testing. In: Lichtlen PR (ed) 6th International Adalat Symposium, pp 280–286Google Scholar
  83. 83.
    Rafflenbeul W, Urthaler F, Russell R, Lichtlen P, James TN (1980) Dilatation of coronary artery stenoses after isosorbide dinitrate in man. Br Heart J 43: 546–549PubMedCrossRefGoogle Scholar
  84. 84.
    Rafflenbeul W, Lichtlen PR (1982) Zum Konzept der “dynamischen” Koronarstenose. Z Kardiol 71: 439–444PubMedGoogle Scholar
  85. 85.
    Rafflenbeul W (1983) Dilatation of coronary artery stenoses with diltiazem i.v. In: Fleckenstein A, Hashimoto K, Herrmann M, Schwartz A, Seipel L (eds) New Calcium Antagonists — Recent Developments and Concepts. Fischer, Stuttgart, pp 181–190Google Scholar
  86. 86.
    Rafflenbeul W, Lichtlen P (1983) Quantitative coronary angiography — evidence of a sustained increase in vascular smooth muscle tone in coronary artery stenosis. Z Kardiol 72 [Suppl. 3]: 87–91PubMedGoogle Scholar
  87. 87.
    Rafflenbeul W, Jost S, Berger C, Lichtlen P (1989) Wirkung von Kalziumantagonisten and Betarezeptorenblockern auf die Koronarweite. Z Kardiol 78 [Suppl 5]: 16–19PubMedGoogle Scholar
  88. 88.
    Reimer KA, Löwe JE, Jennings RB (1977) Effects of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation 55: 581–587PubMedGoogle Scholar
  89. 89.
    Rizzon P, Scrutinio D, Mangini SG, Lagioia R, de Toma L (1986) Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest. Eur Heart J 7: 67–76Google Scholar
  90. 90.
    Robb-Nicholson C, Currie WD, Wechsler A (1978) Effects of verapamil on myocardial tolerance to ischemic arrest. Circulation 58 [Suppl I]: 1119 — I123Google Scholar
  91. 91.
    Rosendorff C (1984) Calcium channel blockers and hypertension. In: Opie LH (ed) Calcium antagonists and cardiovascular disease. Raven Press, New York, pp 323–331Google Scholar
  92. 92.
    Rosenthal SJ, Ginsberg R, Lamb IH, Bairn DS, Schroeder JS (1980) Efficacy of diltiazem for control of symptoms of coronary arterial spasm. Am J Cardiol 46: 1027–1032PubMedCrossRefGoogle Scholar
  93. 93.
    Ross Jr. J (1989) Mechanisms of regional ischemia and antianginal drug action during exercise. Progr Cardiovasc Dis 31: 455–466CrossRefGoogle Scholar
  94. 94.
    Rouleau JL, Chatterjee K, Ports TA, Doyle MB, Hiramatsu B, Parmley W (1983) Mechanism of relief of pacing-induced angina with oral verapamil: reduced oxygen demand. Circulation 67: 94–100PubMedCrossRefGoogle Scholar
  95. 95.
    Schanzenbächer P, Liebau G, Deeg P, Kochsiek K (1982) Koronarsinusfluß and myokardialer Sauerstoffverbrauch nach intrakoronarer Nifedipininjektion bei Patienten mit koronarer Herzkrankheit. Z Kardiol 71: 393–396PubMedGoogle Scholar
  96. 96.
    Schulz W, Krauss G, Kaltenbach M, Kober G (1981) Einfluß von intrakoronarem and intravenösem Nifedipin auf die allgemeine and lokale Gefäßweite von epikardialen Koronararterien bei stabiler Angina pectoris — ein antianginöser Wirkaspekt? Z Kardiol 70: 809–815Google Scholar
  97. 97.
    Serruys PW, Brower RW, ten Katen HJ, Born AH, Hugenholtz PG (1981) Regional wall motion from radiopaque markers after intravenous and intracoronary injections of nifedipine. Circulation 63: 584–591PubMedCrossRefGoogle Scholar
  98. 98.
    Serruys PW, Hooghondt TEH, Reiber JHC, Slager C, Brower RW, Hugenholtz PG (1983) Influence of intracoronary nifedipine on left ventricular function, coronary vasomobility, and myocardial oxygen consumption. Br Heart J 49: 427–433PubMedCrossRefGoogle Scholar
  99. 99.
    Sherman LG, Liang CS, Boden WE, Hood WB (1981) The effect of verapamil on mechanical performance of acutely ischemic and reperfused myocardium in the conscious dog. Circ Res 48: 224–230PubMedGoogle Scholar
  100. 100.
    Sherman LS, Liang CS (1983) Nifedipine in chronic stable angina: a double-blind placebo controlled crossover trial. Am J Cardiol 51: 706–711PubMedCrossRefGoogle Scholar
  101. 101.
    Simon R (1984) Kalziumantagonisten: Wirkung auf periphere and koronare Hämodynamik. Z Kardiol 73 [Suppl 2]: 79–88PubMedGoogle Scholar
  102. 102.
    Singh BN, Roche AHG (1977) Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J 94: 593–599PubMedCrossRefGoogle Scholar
  103. 103.
    Singh BN (1986) The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 21:109 S-119 SGoogle Scholar
  104. 104.
    Somlyo AP (1985) Excitation-contraction coupling in smooth muscle. Circ Res 57: 497–507PubMedGoogle Scholar
  105. 105.
    Spedding M (1985) Calcium antagonists subgroups. Trends Pharmacol Sci 6: 109–114CrossRefGoogle Scholar
  106. 106.
    Steenbergen C, Murphy E, Levy L, London RE (1987) Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat hearts. Circ Res 60: 700–707PubMedGoogle Scholar
  107. 107.
    Strauss WE, McIntyre S, Parisi AF, Shapiro W (1982) Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol 49: 560–566PubMedCrossRefGoogle Scholar
  108. 108.
    Sturek M, Thayer SA, Miller RJ (1988) Intracellular calcium release activates calcium-permeable ion-channels in coronary artery smooth muscle cells. Biophys J 53: 561 (abstr.)Google Scholar
  109. 109.
    Tan ATH, Sadick N, Kelley DT, Harris PJ, Freedman SB, Bautovich G (1982) Verapamil in stable effort angina: effects on left ventricular function evaluated with exercise radionuclide ventriculography. Am J Cardiol 49: 425–430PubMedCrossRefGoogle Scholar
  110. 110.
    Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD (1985) A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 5: 717–722PubMedCrossRefGoogle Scholar
  111. 111.
    Tilton RG, Larson KB, Cole PA, Williamson JR (1984) Diltiazem prevents coronary vascular resistance and permeability changes following no-flow ischemia. Fed Proc 43: 335 (abstr.)Google Scholar
  112. 112.
    Tsien KRW, Bean BP, Hess P, Lansman JB, Nilius B, Nowycky MC (1986) Mechanism of calcium channel modulation by beta-adrenergic agents and dihydropyridine calcium agonists. J Mol Cell Cardiol 18: 691–710PubMedCrossRefGoogle Scholar
  113. 113.
    Tsien RW (1989) Calcium channels as molecular transducers in heart, smooth muscle, and sympathetic neurons. Circulation 80 [Suppl II]:IIA—IIBGoogle Scholar
  114. 114.
    Tzivoni D, Keren A, Gavish A, Benhorin J, Stern S (1987) Guiding anti-ischemic therapy by Hotter monitoring. In: v. Arnim Th, Maseri A (eds) Silent ischemia, Steinkopff, Darmstadt, pp 177–183Google Scholar
  115. 115.
    Urquhart J, Patterson RE, Bacharach SL, Green MV, Speir EH, Aamodt R, Epstein SE (1984) Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs. Circulation 69: 382–390PubMedCrossRefGoogle Scholar
  116. 116.
    van Breemen C, Siegel B (1980) The mechanism of alpha-adrenergic activation of the dog coronary artery. Circ Res 46: 426–429PubMedGoogle Scholar
  117. 117.
    van den Brand M, Remme WJ, Meesters GT, Tiggelaar-de Widt J, de Ruiter R, Hugenholtz PG (1975) Hemodynamic effects of nifedipine in patients catheterized for coronary artery disease. In: Braasch W, Kroneberg G (eds) Second International Adalat Symposium, Springer, Berlin Heidelberg New York Tokyo, pp 145–152Google Scholar
  118. 118.
    van Zwieten PA (1985) Calcium antagonists — terminology, classification and comparison. Drug Res 35: 298–301Google Scholar
  119. 119.
    Vanhoutte PM (1987) The expert committee of the World Health Organisation on classification of calcium antagonists: the viewpoint of the raporteur. Am J Cardiol 59: 3AGoogle Scholar
  120. 120.
    Vatner SF, Hintze TH (1982) Effects of a calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation 66: 579–588PubMedCrossRefGoogle Scholar
  121. 121.
    Wagniart P, Ferguson RJ, Chaitman BR, Achard F, Benacerraf A, Delanguenhagen B, Morin B, Pasternac A, Bourassa MG (1982) Increased exercise tolerance and reduced electrocardiographic ischemia with diltiazem in patients with stable angina pectoris. Circulation 66: 23–28PubMedCrossRefGoogle Scholar
  122. 122.
    Ware AJ, Johnson PC, Smith M, Salzman EW (1986) Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and Quin 2. Circ Res 59: 39–42PubMedGoogle Scholar
  123. 123.
    Warltier DC, Meils CM, Gross GJ, Brooks HL (1981) Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (BAY K5552), a new dihydropyridine calcium antagonist. J Pharmacol Exp Ther 228: 296–302Google Scholar
  124. 124.
    Weintraub WS, Akizuki S, Agarwal JB, Bodenheimer MM, Banka VS, Helfant RH (1982) Comparative effects of nitroglycerin and nifedipine on myocardial blood flow and contraction during flow-limiting coronary stenosis in the dog. Am J Cardiol 50: 281–288PubMedCrossRefGoogle Scholar
  125. 125.
    Weishaar R, Ashikawa K, Bing RJ (1979) Effect of diltiazem, a calcium antagonist, on myocardial ischemia. Am J Cardiol 43: 1137–1143PubMedCrossRefGoogle Scholar
  126. 126.
    Winniford MD, Johnson SM, Mauritson DR, Relias JS, Redish GA, Willerson JT, Hillis LD (1982) Verapamil therapy for Prinzmetal’s variant angina: comparison with placebo and nifedipine. Am J Cardiol 50: 913–918PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1990

Authors and Affiliations

  • Wolf Rafflenbeul
    • 1
  1. 1.Division of CardiologyHannover Medical SchoolHannover 61Germany

Personalised recommendations